Investigating the possible causal role of coffee consumption with prostate cancer risk and progression using Mendelian randomization analysis
Year: 2016
Type: article
Study design: Observational Study
Abstract: Coffee consumption has been shown in some studies to be associated with lower risk of prostate cancer. However, it is unclear if this association is causal or due to confounding or reverse causality. We conducted a Mendelian randomisation analysis to investigate the causal effects of coffee consumption on prostate cancer risk and progression. We used two genetic variants robustly associated with caffeine intake (rs4410790 and rs2472297) as proxies for coffee consumption in a sample of 46,687 men of European ancestry from 25 studies in the PRACTICAL consortium. Associations between genetic variants and prostate cancer case status, stage and grade were assessed by logistic regression and with all-cause and prostate cancer-specific mortality using Cox proportional hazards regression. There was no clear evidence that a genetic risk score combining rs4410790 and rs2472297 was associated with prostate cancer risk (OR per additional coffee increasing allele: 1.01, 95% CI: 0.98,1.03) or having high-grade compared to low-grade disease (OR: 1.01, 95% CI: 0.97,1.04). There was some evidence that the genetic risk score was associated with higher odds of having nonlocalised compared to localised stage disease (OR: 1.03, 95% CI: 1.01, 1.06). Amongst men with prostate cancer, there was no clear association between the genetic risk score and all-cause mortality (HR: 1.00, 95% CI: 0.97,1.04) or prostate cancer-specific mortality (HR: 1.03, 95% CI: 0.98,1.08). These results, which should have less bias from confounding than observational estimates, are not consistent with a substantial effect of coffee consumption on reducing prostate cancer incidence or progression.
Source: International Journal of Cancer
DOI: 10.1002/ijc.30462
Authors: Amy E. Taylor, Richard M. Martin, Milan S. Geybels, Janet L. Stanford, Irene Shui, Rosalind Eeles, Doug Easton, Zsofia Kote‐Jarai, Ali Amin Al Olama, Sara Benlloch, Kenneth Muir, Graham G Giles, Fredrik Wiklund, Henrik Gronberg, Christopher A Haiman, Johanna Schleutker, Børge G. Nordestgaard, Ruth C Travis, David Neal, Nora Pashayan, Kay‐Tee Khaw, William Blot, Stephen Thibodeau, Christiane Maier, Adam S Kibel, Cezary Cybulski, Lisa Cannon‐Albright, Hermann Brenner, Jong Park, Radka Kaneva, Jyotsna Batra, Manuel R Teixeira, Hardev Pandha, Jenny Donovan, Marcus R. Munafò
Institutions: University of Bristol, MRC Integrative Epidemiology Unit, University Hospitals Bristol NHS Foundation Trust, NIHR Bristol Nutrition Biomedical Research Unit, Fred Hutch Cancer Center, University of Washington, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, University of Cambridge, University of Manchester, The University of Melbourne, Cancer Council Victoria, Karolinska Institutet, University of Southern California, USC Norris Comprehensive Cancer Center, University of Turku, Fimlab (Finland), University of Tampere, Herlev Hospital, Copenhagen University Hospital, University of Oxford, Addenbrooke's Hospital, University College London, International Epidemiology Institute, Mayo Clinic, University Hospital Ulm, Brigham and Women's Hospital, Washington University in St. Louis, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, International Hereditary Cancer Center, Pomeranian Medical University, University of Utah, German Cancer Research Center, Deutsches Konsortium für Translationale Krebsforschung, Moffitt Cancer Center, Medical University of Sofia, Queensland University of Technology, Australian Prostate Centre, Universidade do Porto, Instituto Português de Oncologia Francisco Gentil, IPO Porto, Instituto de Ciências Biomédicas Albel Salazar, University of Surrey
Language: English
Topic: Coffee research and impacts
Subfield: Pharmacology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $2,379
Funders: Cancer Research Institute, Breast Cancer Research Foundation, Ovarian Cancer Research Fund, American Society of Clinical Oncology, McGill University, National Cancer Research Institute, United Kingdom Clinical Research Collaboration, Royal Marsden NHS Foundation Trust, University Hospitals Bristol NHS Foundation Trust, Génome Québec, Cancer Research UK, National Institute for Health and Care Research, British Heart Foundation, European Commission, University of Bristol, Australian Institute of Health and Welfare, Australian Government, National Institutes of Health, Canadian Institutes of Health Research, Medical Research Council, Economic and Social Research Council, National Health and Medical Research Council, Cancer Council Victoria, National Cancer Institute
Awards: G1025567081, G1079453547, G1094733267, G1131969086, G1161123863, G1164366582, A genome-wide association study for breast cancer in BRCA1 mutation carriers, G1227813248, Southern Community Cohort Study, G1295075329, NIHR Senior Investigator Award, G1336335877, G1508859565, G1584405745, G1587186860, G1588059303, G1589121050, G1616122786, G173885373, G1767914659, G1797923650, G188264227, G2020998235, G2084344077, G2313227773, G235045266, G236237718, G2373099447, G2373759246, G2445392763, G2453522775, G2620578876, G2642749895, G271288088, G2718683818, G2734198957, G2745390170, G2767147452, G2778851566, G2854377419, G2993358891, G3177576377, G3188551179, G3248832364, The UK Centre for Tobacco Control Studies, G3344456887, G349533334, G3575964969, G3607452959, G3729156826, Elucidating Loci Involved in Prostate Cancer Suceptibility, G3794179797, G380538514, G3891343362, G4015216323, G4043398722, G4044476773, G4098640521, G4119975330, G4167275758, G4192692896, G4197410787, G4278807696, G4324473162, G4333708648, G4393399965, G4395940750, G4662672464, G4727172548, G4915529853, G5009853252, G5019474394, G5035440390, G5048543170, G5347321386, G5373760811, G5378155244, G5395379871, G5433877598, G5486405922, G5616697689, G5756664977, The ProtecT trial - evaluating the effectiveness of treatments for clinically localised prostate cancer, G5850682332, G586064783, G5865683244, G5897142711, G5952534786, G6073614834, G6119919417, NIHR Senior Investigator Award, G6177794165, G6228767644, G6229591247, G6294906247, G6366270716, G6421092503, G6562605244, G6594529311, G6682065591, Epidemiology of Chronic Disease, Health Interventions and DNA Studies, G6723261869, G6794500166, G6850174406, G6850179540, G6858204494, G6955841523, G697149933, G6986701655, G7006486244, G7129459928, G728243498, G7356264847, G7372524322, G7383316951, G7400227903, G7410254275, G7510707455, G751661945, G7557895011, G7570682278, G76752795, G7766069511, G7808646444, G7891086452, G790382466, G8062165187, G8092145710, G8123808567, G8209208257, G8284071903, G8344269847, Collaborative Oncological Gene-environment Study, G8450993173, G8473384893, G856283587, Risk and prognostic factors for breast cancer of different immunohistochemical subtypes, G8834430567, G8853615787, G8854317076, G8908128081, G8924490982, Head injury: monitoring and optimising cerebral metabolism to improve outcome, G8959936493, G8974852769, G9000048109, G9000081378, G9000175716, G9000194421, G9000200580, G9000282203, G9000301350
OpenAlex ID: W2530568549